Combination therapy using active immunotherapy
AssigneeImmatics Biotechnologies GmbH
InventorsHarpreet Singh, Niels Emmerich, Nobert Hilf, Steffen Walter, Toni Weinschenk
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of treating cancer in a mammal comprising administering to the mammal a combination therapy comprising a vaccine and a multi-kinase inhibitor, wherein the vaccine comprises an isolated tumor associated peptide having the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or class-II. Preferably the multi-kinase inhibitor is sunitinib malate and/or sorafenib tosylate or a pharmaceutically acceptable salt thereof.
Claims16
A method of treating a neoplastic disorder in a mammal comprising administering to the mammal a vaccine and sunitinib malate, wherein the vaccine comprises a plurality of isolated tumor associated peptides having the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or class-II and the plurality of isolated tumor associated peptides consist of the following peptides:
- SEQ ID NO:1 (SVASTITGV);
- SEQ ID NO:2 (VMAGDIYSV);
- SEQ ID NO:3 (ALADGVQKV);
- SEQ ID NO:4 (LLGATCMFV);
- SEQ ID NO:5 (SVFAGVVGV);
- SEQ ID NO:
- 6 (ALFDGDPHL);
- SEQ ID NO:7 (YVDPVITSI);
- SEQ ID NO:8 (SQDDIKGIQKLYGKRS);
- SEQ ID NO:9 (STAPPVHNV);
- and SEQ ID NO:10 (LAALPHSCL).
Dependencies are inferred from the claim text.